Ocul Immunol Inflamm. 2013 Aug;21(4):310-6. doi: 10.3109/09273948.2013.775312. Epub 2013 Apr 25.
To report an experience with infliximab in severe corticosteroid-resistant Vogt-Koyanagi-Harada (VKH) disease.
Interventional case series.
The medical records of 2 adult patients were reviewed.
Both patients had a visual acuity reduced to hand motion perception bilaterally after 1 month of high-dose corticosteroid therapy, due to multiple exudative retinal detachment involving the fovea. Visual acuity and OCT findings improved immediately after the first infliximab infusion, retinal detachments fully resolved after 1 month and visual acuity returned to normal within 6 months. Despite a negative pretreatment screening, one patient developed multivisceral tuberculosis, which led to infliximab discontinuation after the 7th infusion and was cured by a 9-month ambulatory antibiotic regimen. The other patient received 11 well-tolerated infliximab infusions. Respectively, 9 and 4 months after infliximab discontinuation both patients had normal vision and OCT findings.
Infliximab showed tremendous therapeutic efficacy in sight-threatening corticosteroid-resistant VKH disease.
报告英夫利昔单抗治疗严重皮质激素耐药性 Vogt-小柳原田（VKH）病的经验。
介入性病例系列。
回顾了 2 例成年患者的病历。
2 例患者在接受大剂量皮质激素治疗 1 个月后，由于累及黄斑的多发性渗出性视网膜脱离，双侧视力均降至手动视力。首次输注英夫利昔单抗后，视力和 OCT 结果立即改善，1 个月后视网膜脱离完全消退，6 个月内视力恢复正常。尽管在预处理筛查时为阴性，但 1 例患者发生多脏器结核，导致第 7 次输注后停用英夫利昔单抗，经 9 个月的门诊抗生素治疗后痊愈。另一名患者接受了 11 次耐受性良好的英夫利昔单抗输注。分别在停用英夫利昔单抗后 9 个月和 4 个月，两名患者的视力和 OCT 检查均正常。
英夫利昔单抗在治疗威胁视力的皮质激素耐药性 VKH 病方面显示出巨大的疗效。
